Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-02T23:31:55.696Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of Antipsychotic Depot Injections in the Maintenance Treatment of Schizophrenia

Published online by Cambridge University Press:  29 January 2018

M. W. P. Carney  and
B. F. Sheffield
M. W. P. Carney
Affiliation:
Northwick Park Hospital and Clinical Research Centre, Watford Road, Harrow, Middlesex
B. F. Sheffield
Affiliation:
University Hospital of South Manchester
Get access Rights & Permissions [Opens in a new window]

Summary

122 Schizophrenic patients treated with injections of fluphenazine ethanate, 97 with fluphenazine decanoate and 199 with flupenthixol decanoate were followed up for mean times of 41, 33 and 21 months respectively. Their progress was compared by examining reasons for discontinuing injections and outcome in three separate groups defined according to first preparation given; relating the events causing patients to discontinue injections or be readmitted to patient-months spent on each drug; and analysing reasons for inter-drug transfers 43 per cent, 24 per cent and 23 per cent respectively of these three groups of patients discontinued the injections. Severe extrapyramidal effects were most frequent with fluphenazine ethanate, intermediate with fluphenazine decanote, and least frequent with flupenthixol. Lack of cooperation was rather more frequent with flupenthixol than with the other drugs. Severe depression occurred with all three. More patients on fluphenazine injections were transferred for any reason to flupenthixol than vice-versa. A case of ‘irreversible’ movement disorder was seen with each preparation. It is suggested that current maintenance doses of flupenthixol decanoate are too low.

Type
Papers
Information
The British Journal of Psychiatry , Volume 129 , Issue 5 , November 1976 , pp. 476 - 481
Copyright
Copyright © Royal College of Psychiatrists, 1976 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alarcon, R. de (1972) Affective symptoms of schizophrenia. Symposium on ‘Current Concepts of Schizophrenia’. World Psychiatric Association, London.Google Scholar
Bott, M. C. (1975) Symposium on ‘Schizophrenia: its biochemistry and therapy’. Schizophrenia Association of Great Britain. Irish Medical Times, 9, 23.Google Scholar
Carney, M. W. P. & Sheffield, B. F. (1975) 42 months experience of flupenthixol decanoate in the maintenance treatment of schizophrenics. Current Medical Research and Opinion, 3, 447—52.CrossRefGoogle Scholar
Gottpries, C. J. (1973) Symposium on Flupenthixol Decanoate, Copenhagen.Google Scholar
Hunter, R., Earl, C. J. & Thornicroft, S. (1964) An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proceedings of the Royal Society of Medicine, 57, 758—62.Google ScholarPubMed
Johnson, D. A. W. (1975) Observations on the dose regime of fluphenazine decanoate in the maintenance therapy of schizophrenia. British Journal of Psychiatry, 126, 457—61.CrossRefGoogle Scholar
Johnson, D. A. W., & Malik, N. A. (1975) A double blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia. Acta Psychiatrica Scandinavica, 51, 257—67.CrossRefGoogle ScholarPubMed
Kennedy, P. F., Hershon, H. I. & McGuire, R. J. (1971) Extra-pyramidal disorders after prolonged phenothiazine therapy. British Journal of Psychiatry, 118, 509—18.CrossRefGoogle Scholar
Miller, R. J., Horn, J. S. & Iversen, L. (1974) The action of neuroleptic drugs on dopamine-stimulated adenosine cyclic 3, 5-monophosphate production in rat neostiatum and limbic forebrain. Molecular Pharmacology, 10, 759—66.Google Scholar
Moller-Nielsen, I., Pederson, V., Nymark, M., Franck, K. F., Boeck, V., Fjalland, B., & Christesen, A. V. (1973) The comparative pharmacology of flupenthixol and some reference neuroleptics. Acta Pharmacologia et Toxicologica, 33, 353—62.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.